Other TGF-β inhibitors, such as SD-208, SD-093 and LY2109761, which are inhibitors of TGFβRI/RII kinases, have shown effects in reducing the tumor burden, reducing abdominal metastases, and improving the survival rates for metastatic pancreatic cancer in a murine model [98,102,103,104]. Here, TGFB1 is linked to neoplasm.